10x Genomics, Inc.
10x Genomics, Inc.
- Market cap
- $6.29B
Your view on TXG
Overview
What the company does, where it operates, and who runs it.
About 10x Genomics, Inc.
- Industry
- Medical - Healthcare Information Services
- Sector
- Healthcare
- CEO
- Serge Saxonov
- Headquarters
- 6230 Stoneridge Mall Road, Pleasanton, CA, US
- Industry
- Medical - Healthcare Information Services
- Sector
- Healthcare
- CEO
- Serge Saxonov
- Headquarters
- 6230 Stoneridge Mall Road, Pleasanton, CA, US
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific.
The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.
Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment.
The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions.
The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for 10x Genomics, Inc.. Starting points for 10x Genomics, Inc.: EPS -$0.51, beta 2.03 — an Medical - Healthcare Information Services name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for 10x Genomics, Inc.. Trailing twelve-month EPS for 10x Genomics, Inc. stands at -$0.51. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Hold
Targets, low to high
Analyst ratings
13 firms, last 12 months- Strong Buy0
- Buy5
- Hold8
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$0.22 | −$0.18 | −$0.63 | −$0.67 |
| Lowest estimate | −$0.34 | −$0.26 | −$0.66 | −$1.12 |
| Highest estimate | $0.11 | −$0.03 | −$0.58 | $0.01 |
| Number of analysts | 3 | 2 | 7 | 8 |
| A year ago | −$0.13 | −$0.101 | −$0.351 | — |
| Growth vs a year ago | −68.8% | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $177.74M | $167.60M | $629.64M | $703.27M |
| Lowest estimate | $173.23M | $156.15M | $621.01M | $670.33M |
| Highest estimate | $182.45M | $179.27M | $637.07M | $735.54M |
| Number of analysts | 10 | 7 | 11 | 12 |
| A year ago | $166.03M | $150.84M | $642.82M | — |
| Growth vs a year ago | +7.1% | +11.1% | −2.1% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for 10x Genomics, Inc.. 10x Genomics, Inc. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| AAgilent Technologies, Inc. | Healthcare | Medical - Diagnostics & Research | $48.0B | ||
| BIOBio-Rad Laboratories, Inc. | Healthcare | Medical - Devices | $9.7B | ||
| GNNSFGenscript Biotech Corporation | Healthcare | Biotechnology | $3.8B | ||
| ILMNIllumina, Inc. | Healthcare | Medical - Diagnostics & Research | $29.2B | ||
| LABStandard BioTools Inc. | Healthcare | Medical - Specialties | $225.0M | ||
| QGENQiagen N.V. | Healthcare | Medical - Diagnostics & Research | $10.2B | ||
| RVTYRevvity, Inc. | Healthcare | Medical - Diagnostics & Research | $16.2B | ||
| TECHBio-Techne Corporation | Healthcare | Biotechnology | $11.4B | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| BTSGUBrightSpring Health Services, Inc. Tangible Equity Unit | Healthcare | NASDAQ | $13.7B | ||
| CCLDCareCloud, Inc. | Healthcare | NASDAQ | $101.3M | ||
| CERTCertara, Inc. | Healthcare | NASDAQ | $1.7B | ||
| CGNSFCognetivity Neurosciences Ltd. | Healthcare | OTC | $8,959 | ||
| CGS.AXCogstate Limited | Healthcare | ASX | — | ||
| CHS.VComprehensive Healthcare Systems, Inc. | Healthcare | TSXV | $7.1M | ||
| CMHSFComprehensive Healthcare Systems, Inc. | Healthcare | OTC | $9.8M | ||
| CMPDCompuMed, Inc. | Healthcare | OTC | $6.3M | ||
| CNONFLynx Global Digital Finance Corporation | Healthcare | OTC | $1,071 | ||
| COGZFCogstate Limited | Healthcare | OTC | $259.0M | ||
| CRVWCareView Communications, Inc. | Healthcare | OTC | $14.6M | ||
| CRWRFCraneware plc | Healthcare | OTC | $850.6M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| ARKKARK Innovation ETF | $7.9B in assets | 2.62% | |
| IWMiShares Russell 2000 ETF | $76.6B in assets | 0.24% | |
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.01% | |
| VBVanguard Small-Cap ETF | $76.9B in assets | 0.10% | |
| PTHInvesco Dorsey Wright Healthcare Momentum ETF | $293M in assets | 3.07% | |
| QMOMAlpha Architect U.S. Quantitative Momentum ETF | $400M in assets | 1.64% | |
| CPAINorthern Lights Fund Trust III - Counterpoint Quantitative Equity ETF | $550M in assets | 1.59% | |
| PSCPrincipal U.S. Small-Cap Multi-Factor ETF | $2.6B in assets | 0.85% | |
Largest holders first, then the funds most concentrated in TXG.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold 10x Genomics, Inc., and how their positions are changing. At a $6.29B market value, institutional positions materially move 10x Genomics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by 10x Genomics, Inc. executives and directors. Shares of 10x Genomics, Inc. have traded between $6.78 and $17.70 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for 10x Genomics, Inc.. Coverage tracks 10x Genomics, Inc. within Medical - Healthcare Information Services (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of 10x Genomics, Inc.